Von Willebrand Factor (VWF) levels are known to increase with age in the general population, but that effect is unclear in von Willebrand disease (VWD) patients. Thus, it is important to assess the trends of VWF levels with age, and the extent and rate of their normalization in patients with VWD. In a retrospective cohort study, we reviewed the medical records of 126 patients between 1996 and 2016 who met the NHLBI diagnostic criteria for type 1 VWD or "Low VWF" (LVWF).
| I N TR ODU C TI ON
Von Willebrand Disease (VWD) is the most common inherited bleeding disorder and is the result of a qualitative or quantitative deficiency in von Willebrand Factor (VWF). VWF plays a vital role in platelet adhesion and aggregation, as well as prolonging the half-life of Factor VIII (FVIII) by preventing its proteolytic cleavage. 1 Ageing is associated with significant changes in the hemostasis pathway, which overall favor increased hypercoagulability. [2] [3] [4] Previous studies in normal patients have shown that coagulation factors including fibrinogen, factor VII, factor VIII, factor VIII, and VWF all tend to increase with age. [2] [3] [4] [5] [6] However, the effect of aging on patients with bleeding disorders such as VWD remains unclear. As the aging population of patients with VWD grows larger, it becomes increasingly important to understand these changes fully. Two recent studies comprising a total of 102 VWD patients, primarily Type 1, showed an age-related increase in VWF levels leading to normalization in a proportion of cases. 7, 8 If the increasing levels of VWF and FVIII observed in healthy subjects is also observed definitively in those with VWD, it can be hypothesized that these patients would eventually "outgrow" their laboratory diagnosis over time by crossing the threshold for the laboratory cut-offs. In turn, such a rise in levels may translate into a reduction in bleeding symptoms related to the disease. Ultimately, this could affect clinical practice by encouraging dose reductions in hemostatic therapy, or precluding it all together. This has important clinical implications given the risk of hyponatremia and other reactions induced by DDAVP, as well as the increased risk of pro-thrombotic complications in the elderly. [7] [8] [9] [10] In this retrospective cohort study of over a hundred patients with Type 1 VWD or "Low von Willebrand Factor" (LVWF), we first investigated the percentage of VWD patients who crossed the diagnostic threshold of the disease due to rising levels through time. We then studied the trends in the levels of VWF related to aging in these patients and calculated the observed rate of change. Willebrand Disease (T1VWD), which was defined based on normal multimers or VWF:RCo/VWF:Ag ratio of 0.6. We excluded patients whose levels were followed for a duration of >5 years.
| Data collection
For each patient, we recorded the gender, age at diagnosis of disease, and current age. We collected all the historically obtained levels of VWF:Ag, VWF:RCo, and FVIII that were ever documented in the electronic medical chart between 1996 and 2016. All blood samples were drawn at our facility and immediately analyzed and processed on site. 
| Laboratory methods

| Outcome measures
The primary outcome studied was complete normalization ( 
| Statistical analyses
In order to assess for differences in age and gender as predictive factors for normalization, we used a logistical regression model identifying CN alone as our positive outcome, and all others as no normalization. Furthermore, we generated linear regression models to demonstrate the positive trends of VWF:Ag, VWF:RCo, and FVIII with time, using all the accepted levels of VWF:Ag, VWF:RCo and FVIII through time that met our criteria in our patient population. The independent variable used was time in days since initial diagnosis, for which we calculated the number of days since the first blood test during initial diagnosis until each subsequent accepted blood draw for every patient. The dependent variables (VWF:Ag, VWF:RCo, and FVIII levels) were collated and plotted against time in days since the initial diagnosis in three separate regression models. The statistical analyses were performed by Secic Statistical Consulting, Inc., which is a third-party consulting company.
| RE S U L TS
| Demographics
Out of the 266 patients registered with the Mary M. Gooley Hemophilia center with a diagnosis of VWD, 235 met our inclusion criteria for the laboratory diagnosis of the disease. 105 patients were excluded due to follow up duration of less than 5 years, such that we report on the remaining 126. The average duration of follow-up for our patients was 10.5 6 3.7 years, ranging between 5 to 20 years (see Figure 1A ).
There was an average of 5.9 points in time per patient at which the accepted levels were drawn. The average baseline levels of VWF:Ag, VWF:RCo, and FVIII for our patients were 40.6 U dL
21
, 36.7 U dL 21 , and 71.3 U dL 21 respectively (Table 1) . 46 (36.5%) of our patients fit the T1VWD criteria at diagnosis, while 80 (63.5%) were labeled as LVWF. The percentage of patients who met the laboratory diagnosis based on deficiencies in VWF:Ag alone, VWF:RCo alone, or both, was 5%, 29%, and 66%, respectively. The average age at which the patients were diagnosed was 27.7 6 16.2, and the age distribution is shown in Figure 1B . Female patients constituted a substantial majority of our study population, with 110 (87%) women.
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| Normalization outcomes
The normalization outcomes in the total population as well as the T1VWD and LVWF groups are shown in Figure 2A . The percentage of patients who achieved the primary outcome of complete in normalization was 27.8%, 19.6%, and 32.5%, in the total, T1VWD, and LVWF populations respectively. The secondary outcome of PN was met in 27.0%, 10.9%, and 36.3%, in the same groups respectively. The percentage of patients who did not achieve any type of normalization was 38% in the total study population. Five patients, all of whom previously belonged to the "partial normalization" group, exhibited a drop in levels below the cut-off threshold in the single parameter that had previously normalized. All five patients were initially diagnosed based on subnormal levels of both VWF:Ag and VWF:RCo, and in four out five, the relapse was evident in the VWF:RCo alone. None of the other normalization groups exhibited any similar sub-threshold drop in levels after normalization. We also calculated CN outcomes based on initial age of diagnosis and initial severity of disease. Figure 2B demonstrates an . The percentages of CN per age group at diagnosis are outlined in Figure 2C .
| Linear regression
The linear regression models plotting all our accepted laboratory data along the time since diagnosis in years are shown in three separate graphs for VWF:Ag, VWF:RCo, and FVIII in Figure 3 . The calculated change with time for VWF:Ag, VWF:RCo, and FVIII was 2.4, 1.4, and
U dL
21
/year, respectively. The positive change with time was statistically significant for all three regression models with P < .001.
| Multiple logistic regression
Age, gender, number of events, and initial disease status were assessed as potential risk factors for normalization. Only initial disease status as LVWF versus T1VWD was found to be a statistically significant risk factor with P < .05. After adjusting for age, gender and the number of events, those with LVWF were almost three times more likely to normalize than those with T1VWD (Odds ratio 5 2.7, 95% Confidence
Interval 5 1.01-7.3, P-value 5 .0468).
| D ISC USSION
To the best of our knowledge, our study is the first of its kind to be conducted in a population in the United States. Furthermore, it appears FIG URE 1 A, Distribution of age at initial diagnosis of VWD among our patient population, shown as number of patients in each age group. B, Number of patients achieving each duration of follow-up in years, from time of diagnosis until the most recent set of accepted VWF levels to include the largest patient population whose levels were ever trended through time, compared to previous studies. Our maximum duration of follow-up, which reached 20 years, is among the longest follow-up durations for repeat testing of VWF levels in VWD patients.
A substantial majority of our study population was female (87%). However, it is not uncommon to see an increased likelihood of women presenting with bleeding symptoms due to more frequent exposure to hemostatic challenges than men, such as those related to menses. Our normalization data suggest that out of every 10 patients with the laboratory diagnosis of Type 1 VWD or LVWF, almost three are expected to completely normalize their levels over an average period of 10 years.
Five patients exhibited a "relapse" phenomenon, where levels that had initially normalized had dropped to again to a sub-threshold point. However, all of these patients had belonged to the "partial normalization" group, defined as normalization of only one parameter (VWF:Ag or VWF:RCo) rather than both. None of the patients in the complete and PN groups, which required both parameters to normalize, displayed this finding. One possible explanation to why "relapse" was observed in a few patients is that the pattern of partial normalization may be due to transient elevations in VWF, which could be related to the release of acute phase reactants, although most testing was done at "steady state" when the patient was being seen on routine follow up. However, be that as it may, robust data was not available regarding comorbid conditions to determine if those with an inflammatory component like rheumatoid arthritis was present. In the study by Sanders et al. over 80% of 71 elderly patients studied had 2 or more comorbid conditions. 7 However in the study by Rydz et al., consistent with our results, there was not a correlation with age. In other words, there was not a higher rate of change in the levels the older the patient was. 8 Regardless of etiology, it could be hypothesized that the normalization of both VWF:Ag and VWF:RCo, rather than one or the other, signifies a more robust and persistent change in hemostasis.
One of the shortcomings of the use of a strict cut-off threshold to define normalization is the fact that it does not account for the change in levels since diagnosis, since our patients had variable levels at the time of initial diagnosis. Furthermore, each of our patients was followed for a different duration of time, with different time points at which laboratories were collected, meaning that the time variable also There are several limitations to our study. The fact that our study was done retrospectively is a major limitation, since the number time points at which the labs were collected could not be controlled, nor of course could we prospectively sample at times of no concurrent contributed to slight increases in the measured levels particularly in patients with borderline disease or LVWF. We minimized in-test variability in levels that could falsely identify patients as initially meeting the laboratory diagnosis, by requiring that the laboratory criteria be met twice. However, since 29% of patients met the laboratory diagnosis of VWD based on VWF:RCo alone, it is possible that a proportion of those patients on repeat testing "normalized" due to the new instrumentation for VWF:RCo activity, although the method stayed the same. This may be an alternative explanation for the transient elevation seen in the patients who relapsed. Lastly, blood types were not included in our study as many of our patients who were diagnosed in the 1990's had missing blood type data.
In summary, we showed an age-related increase in VWF levels in Type 1 and LVWF patients with the clinical ramifications being that it led to rescinding of the laboratory diagnosis in nearly a third of patients. However, and most importantly, whether the observed pattern of normalization in patients with VWD corresponds to a mitigation in bleeding symptoms is unclear. Previous data has been contradictory.
For example, the study by Sanders et al. showed no mitigation in FIG URE 3 Linear regression models showing levels of (A) VWF: Ag, (B) VWF:RCo, and (C) FVIII with time since diagnosis. The dots represent all accepted data points in our study population, and the lines connecting them indicate data from the same patient. All three models demonstrate a statistically significant positive trend with P < .001
bleeding symptoms, while a recent abstract by Seaman et al. described
age-related amelioration of bleeding symptoms in patients with T1VWD. 7, 12 This in part may be in due to the variable methods through which bleeding is evaluated and quantified, as well as variations in patients needing interventions and the intensity of the intervention. We plan to direct our next phase of the study to evaluate for bleeding symptoms through standardized questionnaires including the ISTH bleeding assessment tool. 13 This in part would be important to understand whether "outgrowing" the laboratory diagnosis corresponds to "outgrowing" the bleeding phenotype. If so, this could compel changes in the management of VWD, such as reducing the dose and frequency of hemostatic therapy, or precluding any hemostatic intervention altogether. This has significant implications in clinical practice since hemostatic therapy can be associated with significant risks such as hyponatremia, transfusion reactions, as well as thrombosis, especially in the elderly population.
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